Skip to content

US · VTRS · DRUG MANUFACTURERS - SPECIALTY & GENERIC

Viatris Inc. (VTRS) intrinsic value and stock valuation

$19.63as of 2026-11-21 · Mkt cap 20.55B

Data updated · price as of 2026-11-21

Fairly valuedIC value is within 20% of the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Viatris Inc. DCF and intrinsic value

InvestorsCraft values VTRS with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from VTRS’s statements →

Viatris Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Drug Manufacturers - Specialty & Generic Canonsburg, PA 15317 viatris.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$14.3B+3.7% 5y CAGRd
20112025
Net income
-$-3.51B
20112025
Free cash flow
$1.94B+28.6% 5y CAGRd
20112025
Total equity
$14.7B-8.5% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$14.3B$14.7B$15.4B$16.3B$17.9B
Operating income-$-2.66B$10.1M$766.2M$1.61B-$-34M
Net income-$-3.51B-$-634.2M$54.7M$2.08B-$-1.27B
EPSd-$-3M-$-531.47K$45.3K$1.71M-$-1.05M
Operating cash flow$2.32B$2.3B$2.8B$3B$3.02B
Capital expenditure-$-378.8M-$-326M-$-474.5M-$-489.4M-$-509.4M
Free cash flow$1.94B$1.98B$2.33B$2.51B$2.51B
Total assets$37.2B$41.5B$47.7B$50B$54.8B
Total debt$14.7B$14.3B$18.4B$19.5B$23.4B
Net debt$13.4B$13.6B$17.4B$18.3B$22.7B
Total equity$14.7B$18.6B$20.5B$21.1B$20.5B
Cash and short-term investments$1.45B$1.09B$1.18B$1.47B$935M
Income statement
20252024202320222021
Revenue$14.3B$14.7B$15.4B$16.3B$17.9B
Cost of revenue$9.29B$9.12B$8.99B$9.77B$12.3B
Gross profit$5.01B$5.62B$6.44B$6.5B$5.58B
Research and development expenses$965.9M$808.7M$805.2M$662.2M$681M
Selling, general and administrative expenses$3.79B$4.43B$4.65B$4.18B$4.53B
Other expenses$2.92B$379.2M$217.1M$40.8M$399.3M
Operating expenses$7.68B$5.61B$5.67B$4.88B$5.61B
Cost and expenses$17B$14.7B$14.7B$14.6B$17.9B
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$471.3M$550M$573.1M$592.4M$636.2M
Depreciation and amortization$2.8B$2.89B$2.74B$3.03B$4.51B
Ebitda-$-395.4M$2.82B$3.52B$6.43B$4.48B
Operating income-$-2.66B$10.1M$766.2M$1.61B-$-34M
Total other income/expenses, net-$-1B-$-633.3M-$-563.3M$1.2B-$-630.4M
Income before tax-$-3.67B-$-623.2M$202.9M$2.81B-$-664.4M
Income tax expense-$-150.1M$11M$148.2M$734.6M$604.7M
Net income-$-3.51B-$-634.2M$54.7M$2.08B-$-1.27B
Weighted average shares outstanding$1.17B$1.19B$1.2B$1.21B$1.21B
Weighted average diluted shares outstanding$1.17B$1.19B$1.21B$1.22B$1.21B
Balance sheet
20252024202320222021
Cash and short-term investments$1.45B$1.09B$1.18B$1.47B$935M
Net receivables$3.35B$3.52B$4.04B$4.14B$4.27B
Inventory$4B$3.85B$3.47B$3.52B$3.98B
Total current assets$9.22B$9.52B$13B$10.6B$10.9B
Property, plant and equipment, net$2.89B$2.92B$3.01B$3.28B$3.48B
Goodwill and intangible assets$21.9B$26.2B$29B$33B$38.2B
Long-term investments$815M$1.35B$1.14B$1.09B$81.4M
Total non-current assets$28B$32B$34.7B$39.4B$43.9B
Total assets$37.2B$41.5B$47.7B$50B$54.8B
Accounts payable$1.29B$1.36B$1.38B$1.16B$1.06B
Short-term debt$2.04B$87.7M$2.02B$1.33B$3.44B
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$7.09B$5.78B$7.78B$6.75B$9.88B
Long-term debt$12.7B$14.2B$16.4B$18.2B$19.9B
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$15.4B$17.1B$19.4B$22.2B$24.5B
Capital lease obligations$178.1M$266.4M$248.4M$262M$287.6M
Total liabilities$22.5B$22.9B$27.2B$28.9B$34.4B
Common stock$12.5M$12.3M$12.2M$12.1M$12.1M
Retained earnings-$-388.3M$3.42B$4.64B$5.18B$3.69B
Accumulated other comprehensive income (loss)-$-2.71B-$-3.21B-$-2.75B-$-2.76B-$-1.74B
Total equity$14.7B$18.6B$20.5B$21.1B$20.5B
Total investments$921.4M$1.7B$1.33B$1.3B$315.2M
Total debt$14.7B$14.3B$18.4B$19.5B$23.4B
Net debt$13.4B$13.6B$17.4B$18.3B$22.7B
Cash flow statement
20252024202320222021
Net income-$-3.51B-$-634.2M$54.7M$2.08B-$-1.27B
Depreciation and amortization$2.8B$2.71B$2.74B$3.03B$4.51B
Stock-based compensation$177.7M$146.1M$180.7M$116.4M$111.2M
Change in working capital-$-2.5B-$-318.6M-$-711.3M-$-922.6M-$-1.8B
Accounts receivable$334.6M$300.1M$78.6M-$-240.3M$59.3M
Inventory-$-106.4M-$-723.4M-$-613.3M-$-259.5M-$-427.6M
Accounts payable-$-168M$36M$314.7M$170.2M-$-70.4M
Net cash provided by operating activities$2.32B$2.3B$2.8B$3B$3.02B
Investments in property, plant and equipment-$-378.8M-$-326M-$-377M-$-489.4M-$-509.4M
Acquisitions, net$0.00-$-350M-$-667.7M$0.00$277M
Net cash used for investing activities-$-427.7M$1.8B-$-764.1M$1.47B-$-117.8M
Common stock issued$2.6M$2.5M$3.1M$3.3M$0.00
Common stock repurchased-$-500.5M-$-250M-$-250M$0.00-$-17.4M
Dividends paid-$-561.2M-$-574.8M-$-575.6M-$-581.6M-$-399M
Net cash used for financing activities-$-1.29B-$-4.33B-$-2.3B-$-3.88B-$-3.01B
Net change in cash$611.9M-$-257.5M-$-268.9M$556.3M-$-143.8M
Cash at end of period$1.35B$736.1M$993.6M$1.26B$706.2M
Operating cash flow$2.32B$2.3B$2.8B$3B$3.02B
Capital expenditure-$-378.8M-$-326M-$-474.5M-$-489.4M-$-509.4M
Free cash flow$1.94B$1.98B$2.33B$2.51B$2.51B
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Viatris Inc.

        Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.

        CEO
        Scott Andrew Smith
        Employees
        30K
        Beta
        0.90

        Explore

        Frequently asked questions

        What is the intrinsic value of Viatris Inc. (VTRS)?

        Viatris Inc. (VTRS) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is VTRS undervalued?

        VTRS trades at a price of $19.63 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.